Clinical trial · Interventional
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
NCT00971867CI-TRIAL-00057669completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Paclitaxel
- interventionNames
- Drug: Paclitaxel
Primary outcomes (5)
- measure
- Number of Participants With SAEs
- timeFrame
- From the first infusion to the completion of study. Approximately up to 28 months
- description
- Number of Participants with SAEs
- measure
- Number of Participants With Adverse Events Leading to Discontinuation
- timeFrame
- From the first infusion to the completion of study. Approximately up to 28 months
- description
- Number of Participants with Adverse Events Leading to Discontinuation
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator
References
Publications (0)
Data not yet available
No reference posted for this study.